Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Reports 22-Percent Slide in Q3 Revenue, Names New CEO

NEW YORK, Nov. 2 (GenomeWeb News) - Compugen said today that revenues for the third quarter declined 22 percent while net losses remained flat.


The company also said it has named Alex Kotzer president and CEO. He started on Sept. 1.


Total revenues for the three months ended Sept. 30 fell to $761,000 from $971,000 year over year. About 87.5 percent of the amount, or $666,000, came from "governmental and other grants," said Compugen


Third quarter R&D spending increased slightly to $3 million from $2.8 million in the previous year.


The company reported that net loss remained flat for the quarter, at approximately $3.6 million, or $.13 per share.


As of Sept. 30, the company had $29.9 million in cash and cash equivalents.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.